Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.
A substantial proportion of patients become colonised with Candida spp during hospital stay, but only few subsequently develop severe infection. Clinical signs of severe infection manifest early but lack specificity until late in the course of the disease, thus representing a particular challenge for diagnosis. Mostly nosocomial, invasive candidiasis occurs in only 1-8% of patients admitted to hospitals, but in around 10% of patients housed in intensive care units where it can represent up to 15% of all nosocomial infections. We review the epidemiology of invasive candidiasis in non-immunocompromised, critically ill patients with special emphasis on disease trends over time, pathophysiology, diagnostic approach, risk factors, and impact. Recent epidemiological data suggesting that the emergence of non-albicans candida strains with reduced susceptibility to azoles, previously linked to the use of new antifungals for empiric and prophylactic therapy in immunocompromised patients, may not have occurred in the critically ill. Management of invasive candidiasis in these patients will be addressed in the December issue of The Lancet Infectious Diseases.
Medical Clinic II, the Medical Intensive Care Unit and the Infection Control Programme, Department of Internal Medicine, University of Geneva Hospitals, Geneva, Switzerland.
Philippe
P
Eggimann
Jorge
J
Garbino
Didier
D
Pittet
D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D014943:Global Health; D006801:Humans; D015994:Incidence; D007362:Intensive Care Units; D008826:Microbial Sensitivity Tests; D011159:Population Surveillance; D012307:Risk Factors; D013045:Species Specificity
D000935:Antifungal Agents